ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
The performance of plasma p-tau217 in Black middle-aged and older adults.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- From Cerebrospinal Fluid to Blood Draw: Plasma p-Tau217 as a Non-Invasive Biomarker for Alzheimer's Disease: A Fagan Nomogram-Based Meta-Analytic Study.Molecular neurobiology · 2026Pooled it
- Plasma Phosphorylated Tau 217 and Incident Mild Cognitive Impairment and Dementia in Older Women.JAMA network open · 2026Trial
- Review
- Atypical involvement of Alzheimer's tau proteins in diseases beyond tauopathies.Life medicine · 2026Review
- Age-related increase in plasma p-tau217 in amyloid-beta-negative cognitively unimpaired individuals affects diagnostic interpretation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma p-tau217, p-tau181, and Aβ42 predict amyloid PET positivity in cognitively unimpaired adults.Alzheimer's research & therapy · 2026Article
- Common Medical Comorbidities, Demographic Factors and Levels of Plasma Biomarkers of Alzheimer's Disease and Neurodegeneration in Black/African American Older Adults.Biomolecules · 2026Article
- Review
- Plasma p-tau217, p-tau181, and Aβ42 Predicts Amyloid PET Positivity in Cognitively Unimpaired Adults.Research square · 2026Article
- Blood-based biomarkers of Alzheimer's disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms.NPJ dementia · 2026Article
- Evaluation of a panel of plasma biomarkers for Alzheimer's disease in a diverse research cohort.Journal of Alzheimer's disease : JAD · 2026Article
- Plasma p-tau217 and incident mild cognitive impairment and dementia in older women: 25-year prospective study in The Women's Health Initiative Memory Study.medRxiv : the preprint server for health sciences · 2025Article
- Blood-based Alzheimer's disease biomarkers in a behavioral neurology clinic: Real-world implementation, clinical utility, and diagnostic performance.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The performance of plasma p-tau217 in Black middle-aged and older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Population disparities in Alzheimer's disease: A systematic review of fluid and neuroimaging biomarkers.Alzheimer's & dementia (Amsterdam, Netherlands)Review
- The clinical value of multimodal neuroimaging in monoclonal antibody therapy for Alzheimer's disease.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionMedical conditions prevalent in Black adults within the United States have been associated with plasma tau phosphorylated at threonine 217 (p-tau217); however, insufficient p-tau217 research has been conducted with Black adults.
methodsParticipants included n = 233 predominantly cognitively unimpaired adults enrolled in the African Americans Fighting Alzheimer's in Midlife study. Subsamples had creatinine (n = 137) and positron emission tomography (PET; amyloid-PET = 65 [amyloid-PET-positive = 16/65]; tau-PET = 70). We tested whether p-tau217 (ALZPath, Inc.) varied by medical condition and amyloid- and tau-PET-positivity status and assessed the diagnostic accuracy of p-tau217.
resultsEstimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m DISCUSSION: Plasma p-tau217 showed promise as an Alzheimer's biomarker in Black adults; however, kidney function and CVD should be considered when interpreting levels. HIGHLIGHTS: Plasma tau phosphorylated at threonine 217 (p-tau217) was tested in a sample of Black middle-aged and older adults. Level of p-tau217 was higher in impaired kidney function and cardiovascular disease. Obesity and diabetes were not related to p-tau217. Level of p-tau217 was higher in amyloid- and tau-PET-positive status. Plasma p-tau217 showed good receiver-operating characteristic area under the curve for abnormal amyloid- and tau-PET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.